Explore Now

How to Select the Right CHO Cell Line for Biologics Development

Summary

Dr. Louis Boon explores the pivotal role of Chinese Hamster Ovary (CHO) cells in biologic drug development and explains how automation and cell line platforms can optimize monoclonality, productivity, and regulatory compliance. Discover expert insights into overcoming cell line development challenges to build a solid foundation for bioprocessing success.

Research highlights

Study Title: Coupling picodroplet microfluidics with plate imaging for the rapid creation of biomanufacturing suitable cell lines with high probability and improved multi-step assurance of monoclonality.
Authors: Pybus, L. P., Kalsi, D., Matthews, J. T., Hawke, E., Barber, N., Richer, R., Young, A., & Saunders, F. L.
Published In: Biotechnol. J., 17, e2100357, 2022
DOI: 10.1002/biot.202100357

Key findings

High-throughput technology: Cyto-Mine® offers high-throughput capabilities that allow for the screening of a large number of single cells and finding the best ones for biomanufacturing.
Precise dispensing and imaging: The precise dispensing and integrated imaging functionalities provide unique opportunities for improved monoclonality assurance.
Reliable and reproducible workflows: The robust and efficient workflows ensure that users can consistently generate cell lines that meet regulatory requirements.

The Next Generation: Cyto-Mine® Chroma

Automate. Accelerate. Analyze millions of cells in a single day.

Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.